Detalhe da pesquisa
1.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Gynecol Oncol
; 169: 64-69, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512912
2.
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
Gynecol Oncol
; 171: 23-30, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36804618
3.
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Gynecol Oncol
; 160(1): 71-76, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33139041
4.
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Cancer
; 126(6): 1274-1282, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31880826
5.
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.
Int J Gynecol Cancer
; 28(6): 1176-1182, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29757876
6.
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission.
Cancers (Basel)
; 15(5)2023 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900251
7.
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
J Clin Oncol
; 39(23): 2594-2604, 2021 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019431